已收盤 10-24 16:00:00 美东时间
-0.070
-1.00%
今日重点评级关注:摩根士丹利:维持Viking Therapeutics"超配"评级,目标价从98美元升至102美元;摩根大通:维持IDEAYA Biosciences"超配"评级,目标价从74美元升至79美元
10-24 09:51
Scotiabank analyst Eric Winmill maintains Metalla Royalty (AMEX:MTA) with a Sector Perform and raises the price target from $5 to $7.5.
10-23 23:16
https://cdn.cboe.com/resources/regulation/rule_filings/pending/2025/SR-CBOE-2025-079.pdf?_gl=1*11wm1t2*_up*MQ..*_ga*NjI3MzA3MTg3LjE3NTk0MTkyMjg.*_ga_5Q99WB9X71*czE3NTk0MTkyMjgkbzEkZzAkd
10-21 02:46
https://mp.weixin.qq.com/s?__biz=MjM5MjYyMTA2Nw==&mid=2649861327&idx=1&sn=7c0c25c7da7235cdaf0d7f4382a82156&chksm=bf4c39ac82835b5ac7505b06686b8427d6791aaf22ba3618e514fc532a50d1f4ec759a8d87a7&mpshare=1&
10-16 21:48
USA News Group News Commentary – Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is acc...
10-15 21:11
AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumorsAlphaMedixTM showed
10-08 13:55
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Break...
09-08 21:30
Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy® (Dose level 2); ORR of 33% (3/9; 3cPR) at 15 mg IDE397 plus 10mg/kg Trodelvy®
09-08 20:07
来源:华兴资本 “华兴资本医疗与生命科技行业周报”定期发布,专注从资本角度解读一周数据,并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域,目...
09-01 08:30
Expands mobility promoting sustainable, transit-oriented growth for New York City communitiesDALLAS, Aug. 27, 2025 /PRNewswire/ -- Jacobs (NYSE:J), in joint venture with HDR, has been selected to provide engineering
08-27 19:51